EUDA (EUDA) faces Nasdaq MVLS deficiency with October 20, 2026 deadline
Rhea-AI Filing Summary
EUDA Health Holdings Limited reported that Nasdaq notified the company on April 23, 2026 that it failed to maintain the required Minimum Market Value of Listed Securities of $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). The notice does not immediately affect trading, and EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its market value close at $35,000,000 or more for at least ten consecutive business days. If EUDA does not regain compliance within this period, its securities will be subject to potential delisting, although the company would have the right to appeal.
Positive
- None.
Negative
- Nasdaq MVLS deficiency and delisting risk: EUDA Health Holdings Limited failed to maintain the required $35 million Minimum Market Value of Listed Securities for 32 consecutive business days and faces potential Nasdaq delisting if it cannot restore MVLS to at least $35,000,000 for ten consecutive business days by October 20, 2026.
Insights
Nasdaq MVLS deficiency puts EUDA’s Nasdaq listing at risk if not cured.
EUDA Health Holdings Limited has fallen below Nasdaq’s required $35 million Minimum Market Value of Listed Securities for 32 consecutive business days. Under Listing Rule 5550(b)(2), this triggers a deficiency status but does not immediately remove the listing.
The company has a 180-day MVLS compliance period until October 20, 2026. To regain compliance, its market value must close at or above $35,000,000 for at least ten consecutive business days. The mechanics link resolution directly to sustained share price and market capitalization levels.
If EUDA does not meet this standard by the deadline, Nasdaq may move to delist the securities, with an appeal process available. The filing also notes there can be no assurances that the company will regain compliance, highlighting ongoing listing risk until market value recovers.
Key Figures
Key Terms
Minimum Market Value of Listed Securities financial
Nasdaq Listing Rule 5550(b)(2) regulatory
MVLS Notice regulatory
Nasdaq Capital Market market
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-40678
EUDA Health Holdings Limited
(Exact Name of Registrant as Specified in its Charter)
60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: +65 6327 1110
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
On April 23, 2026, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).
The MVLS Notice has no immediate effect on the listing of the Company’s securities on Nasdaq and the Company has been provided a period of 180 calendar days from the date of the MVLS Notice, or until October 20, 2026, in which to regain compliance (the “MVLS Compliance Period”). In order to regain compliance with Nasdaq Listing Rule 5550(b)(2), the Market Value of Listed Securities of the Company must close at $35,000,000 or more for a minimum of ten consecutive business days during the MVLS Compliance Period.
In the event that the Company does not regain compliance with Nasdaq Listing Rule 5550(b)(2) within the MVLS Compliance Period, Nasdaq will provide notice to the Company that its listed securities will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq’s determination to delist its securities. However, there can be no assurances that Nasdaq would be able to regain compliance with all applicable requirements for continued listing on the Nasdaq Capital Market.
Exhibits
| 99.1 | Press release dated April 27, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: April 27, 2026 | ||
| EUDA Health Holdings Limited | ||
| By: | /s/ Alfred Lim | |
| Name: | Alfred Lim | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
Singapore. April 27, 2026 (Globe Newswire) - EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).
The MVLS Notice has no immediate effect on the listing of the Company’s securities on Nasdaq and the Company has been provided a period of 180 calendar days from the date of the MVLS Notice, or until October 20, 2026, in which to regain compliance (the “MVLS Compliance Period”). In order to regain compliance with Nasdaq Listing Rule 5550(b)(2), the Market Value of Listed Securities of the Company must close at $35,000,000 or more for a minimum of ten consecutive business days during the MVLS Compliance Period.
In the event that the Company does not regain compliance with Nasdaq Listing Rule 5550(b)(2) within the MVLS Compliance Period, Nasdaq will provide notice to the Company that its listed securities will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq’s determination to delist its securities. However, there can be no assurances that Nasdaq would be able to regain compliance with all applicable requirements for continued listing on the Nasdaq Capital Market.
For investor and media inquiries, please contact:
Christensen Advisory
Christian Arnell
Phone: +852 2117 0861
Email: christian.arnell@christensencomms.com